Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
A senolytic research tool. The protocol library points at mouse work (Baar et al., Cell 2017). Apoptosis up and senescence down on this sheet are that mouse map. They are not a human result.
A generic FOXO4 peptide and FOXO4-DRI are not the same chemical. Neither one is an anti-aging treatment on this sheet.
The mouse map is a disrupted FOXO4-p53 survival signal inside senescent cells, then apoptosis of those cells.
Human senolytic trials of this peptide are absent in the protocol library. The arrows are the mouse map, not a clearance to use it.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Senolytic cycle · unverified
Longevity forums describe FOXO4-DRI cycles. The protocol library grades that F. The mouse paper is not those posts, and the posts are not a trial.
From the Catalyst protocol research library. Community schedules there are Grade F and are not a dose.